GUTS NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Fractyl Health, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 0.77 USD
-4.6% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -6.2% below the Trend Line and sits at 19.1% of its 52-week range. The latest completed week returned -4.6%, after a 4.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 60/100. Near-term considerations: earnings are due in 13d.

Setup score 33 out of 100
Latest Close 0.77 USD 24 Jul 2026
1W Return -4.6% latest completed week
4W Return 4.0% short-term follow-through
12W Return 10.5% quarterly tape
Trend Breadth 13.5% 7 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.6% Latest completed week; four-week move 4.0%. Indicator stack 7/56 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 60/100 69 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -6.2% below the Trend Line and sits at 19.1% of its 52-week range. The latest completed week returned -4.6%, after a 4.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2712-week average 0.23

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.27Current proprietary activity-pressure read.
Buy signals3Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 4.0% over four weeks, 10.5% over 12 weeks, and -59.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.6%
4W4.0%
12W10.5%
26W-63.0%
52W-59.7%
Active trend streak0 weeks
Active weeks in one year7
Trend breadth13.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.36Latest activity-pressure read.
Pressure change-6.7%Four-week change in activity pressure.
Leadership-34.43Latest relative-leadership reading.
RS change21.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength61/100Blend of value, momentum, and quality. Underlying universe rank 40; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality53/100Profitability and accounting quality. Underlying universe rank 48; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth55/100Revenue and earnings growth. Underlying universe rank 46; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-72.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-425.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-69.8%
Net share repurchases relative to market value.
Shareholder yield
-69.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment60/100

Weighted news tone is neutral across 69 relevant articles.

28 positive · 37 neutral · 4 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-68.4%Distance below the 52-week high.
13-week volatility11.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher18 of 268 weeks finished lower.
Best week+25.3%Week of 12 Jun.
Worst week-78.0%Week of 30 Jan.
Latest week-4.6%Week of 24 Jul.

Shape of recent returns

Strong gains9
Modest gains9
Flat weeks0
Modest losses1
Sharp losses7
Recent vol11.2%13-week weekly-return volatility.
Base vol16.9%52-week weekly-return volatility.
Up/down split30/21Count of positive and negative weeks in the 52-week window.
Average skew9.8% / -12.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape27/100

Trend, activity pressure, participation, and risk combine to a 27/100 tape read.

 Indicator analysis32/100

Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.27; No reversal markers Factors55/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 98; Small Cap Core rank 51 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment60/100

Weighted news tone is neutral across 69 relevant articles.

Fractyl Health Inc (GUTS) Cash Flow Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.77 USD-4.6%0.82 USD2.59 USD0.36-34.4311.0MOff
17 Jul 20260.81 USD2.2%0.87 USD2.60 USD0.34-34.0618.2MOff
10 Jul 20260.79 USD4.0%0.92 USD2.62 USD0.31-39.493.7MOff
3 Jul 20260.76 USD2.6%0.97 USD2.63 USD0.36-41.813.0MOff
26 Jun 20260.74 USD-13.4%1.01 USD2.64 USD0.39-43.895.5MOff
19 Jun 20260.86 USD1.0%1.04 USD2.66 USD0.43-39.3212.5MOff
12 Jun 20260.85 USD25.3%1.06 USD2.67 USD0.45-40.067.0MOff
5 Jun 20260.68 USD-15.8%1.07 USD2.69 USD0.59-52.329.3MOff
29 May 20260.81 USD-11.4%1.08 USD2.71 USD0.63-47.325.8MOff
22 May 20260.91 USD5.7%1.10 USD2.72 USD0.45-40.278.3MOff
15 May 20260.86 USD14.0%1.11 USD2.74 USD0.17-43.9623.1MOff
8 May 20260.75 USD7.9%1.13 USD2.75 USD-0.24-51.897.6MOff
1 May 20260.70 USD12.8%1.15 USD2.77 USD-0.58-53.8810.5MOff
24 Apr 20260.62 USD8.9%1.18 USD2.79 USD-0.72-59.258.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.